Gritstone, Genevant Sciences in License Agreement for COVID-19 Vaccine

 Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate, today announced an agreement pursuant to which Gritstone has obtained a nonexclusive license to Genevant’s LNP technology to develop and commercialize self-amplifying RNA (SAM) vaccines against SARS-CoV-2, the virus that causes COVID-19. Genevant’s LNP platform is clinically validated and part of Gritstone’s SAM neoantigen-based cancer immunotherapy now in Phase 2 testing.

https://www.globenewswire.com/news-release/2021/01/20/2161371/0/en/Gritstone-and-Genevant-Sciences-Announce-License-Agreement-for-COVID-19-Vaccine.html